Clinical trials: Cytokine Release Syndrome
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
Non-Hodgkin Lymphoma
Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma
This phase I trial tests the safety and side effects of siltuximab in preventing CAR T cell therapy related cytokine release syndrome in patients with CD19 positive non-Hodgkin lymphoma.
- Trial name
- NCT05665725
- Testing
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Timothy Voorhees
SIRS, Cytokine Storm
Cytokine Hemoadsorption in ECMO Patients
Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability.
- Conditions
- SIRS, Cytokine Storm, Cardiogenic Shock, Cardiac Arrest
- Trial name
- NCT04901338
- Where
- Slovenia
- Volunteers
- 25 people
- Sponsor
- University Medical Centre Ljubljana
Dialysis; Complications, COVID-19
Immune Response Following COVID-19 in Hemodialysis Patients
Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19.
- Conditions
- Dialysis; Complications, COVID-19, Cytokine Storm
- Trial name
- IMMUNOVIDIAL (NCT05307601)
- Where
- France
- Volunteers
- 21 people
- Sponsor
- AURA Paris
COVID-19
INB03 for the Treatment of Pulmonary Complications From COVID-19
The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.
- Trial name
- NCT04370236
- Testing
- INB03
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- Inmune Bio, Inc.
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
COVID-19, Acute Respiratory Distress Syndrome
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- SINK COVID-19 (NCT04365985)
- Testing
- Naltrexone, Ketamine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Corewell Health East
Covid19, Cytokine Release Syndrome
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with…
- Trial name
- NCT04540120
- Testing
- dapansutrile capsules
- Where
- 10 sites in United States, Switzerland
- Volunteers
- 49 people
- Sponsor
- Olatec Therapeutics, Inc.
COVID-19, COVID-19 Pneumonia
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
Check the efficacy, safety and tolerability of the compound Modified isothymol against the SARS-CoV-2 agent in patients COVID-19.
- Conditions
- COVID-19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05445089
- Testing
- Carvacrol, Control group
- Where
- Venezuela
- Volunteers
- 600 people
- Sponsor
- Instituto Venezolano de Investigaciones Cientificas
Covid19, Cytokine Storm
Anakinra, COVID-19, Cytokine Storm
The clinical syndrome associated with infection of the Coronavirus Disease 2019 (COVID-19) is notable for its variable clinical expression.
- Conditions
- Covid19, Cytokine Storm, Mechanical Ventilation Complication
- Trial name
- SOBI (NCT04603742)
- Testing
- Anakinra, 0.9% Saline
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Covid19
Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)
Currently, there are few approved treatments for COVID-19, antiretroviral (remdesivir) and corticoids. With about 15% of COVID-19 patients suffering from severe disease health system will be overwhelmed.
- Trial name
- STRUCK (NCT04724629)
- Testing
- Ixekizumab, Aldesleukin, Colchicine
- Where
- 2 sites in Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
COVID-19, Critical Illness
Immune Modulation by Exosomes in COVID-19
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
- Conditions
- COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis
- Trial name
- IMECOV19 (NCT05191381)
- Testing
- Application of exosomes in a whole blood assay
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Ulm
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Acute Decompensated Heart Failure, Cytokine Storm
Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure
Assess the anti-inflammatory effects of short-term Copaxone therapy on patients with acute decompensated heart failure. Trial Design An open-label, randomized, prospective trial of patients hospitalized due to acute…
- Conditions
- Acute Decompensated Heart Failure, Cytokine Storm, Inflammatory Response, Heart Failure
- Trial name
- Copaxone (NCT06003972)
- Testing
- Copaxone, guideline directed medical therapy (GDMT)
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- Hadassah Medical Organization
COVID-19
Etoposide in Patients With COVID-19 Infection
This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection.
- Trial name
- NCT04356690
- Testing
- Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Boston Medical Center
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
B-Cell Non-Hodgkin Lymphoma
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell non-Hodgkin lymphoma who are receiving CD-19…
- Trial name
- NCT04359784
- Testing
- Anakinra, X-Ray Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Coronavirus Infections
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
The aim of this study is to analyze if administration of conestat alfa for 72 hours in addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2 pneumonia (WHO Ordinal Scale Score 3 or 4) reduces…
- Trial name
- NCT04414631
- Testing
- Conestat alfa
- Where
- 5 sites in Brazil, Mexico and 1 more
- Volunteers
- 80 people
- Sponsor
- University Hospital, Basel, Switzerland
SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
To explore the efficacy of treatment of pulmonary cytokine storm induced by SARS-CoV2 with a monoclonal antibody to IL-2 (Basiliximab) in addition to current standard of care vs current standard of care with the primary efficacy…
- Conditions
- SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm
- Trial name
- FWCSWG-IL-2 (NCT05013034)
- Testing
- Basiliximab Injection
- Volunteers
- 300 people
- Sponsor
- Fort Worth Clinical Sciences Working Group
Stem Cell Transplant Complications, Cytokine Release Syndrome
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
Phase II, randomized controlled, unblinded clinical trial. Will evaluate whether the administration of oral cyclosporine started on day 0 of transplantation is effective in reducing the incidence of cytokine release syndrome…
- Trial name
- NCT04781803
- Testing
- Cyclosporine
- Where
- Mexico
- Volunteers
- 32 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez